Company profile

Stephen Christopher Linthwaite
Incorporated in
Fiscal year end
IRS number

FLDM stock data

FINRA relative short interest over last month (20 trading days) ?

Investment data

Data from SEC filings
Securities sold
Number of investors


8 Nov 19
22 Feb 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue 26.5M 28.2M 30.11M 32.33M
Net income -12.89M -13.75M -25.47M -14.78M
Diluted EPS -0.19 -0.2 -0.44 -0.36
Net profit margin -48.64% -48.78% -84.57% -45.71%
Operating income -13.82M -14.64M -14.21M -11.12M
Net change in cash 1.84M -41.59M 47.95M -18.14M
Cash on hand 25.89M 24.05M 65.63M 17.69M
Cost of revenue 12.46M 12.83M 13.12M 13.51M
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 112.96M 101.94M 104.45M 114.71M
Net income -59.01M -60.54M -75.99M -53.32M
Diluted EPS -1.49 -1.84 -2.62 -1.86
Net profit margin -52.24% -59.38% -72.75% -46.48%
Operating income -48.16M -58.36M -73.19M -50.16M
Net change in cash -2.44M 6.15M -3.91M -5.6M
Cash on hand 17.69M 20.13M 13.98M 17.89M
Cost of revenue 51.32M 49.96M 300K 300K

Financial data from Fluidigm earnings reports

90.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 99 123 -19.5%
Opened positions 12 20 -40.0%
Closed positions 36 33 +9.1%
Increased positions 37 47 -21.3%
Reduced positions 36 40 -10.0%
13F shares
Current Prev Q Change
Total value 252.96M 292.19M -13.4%
Total shares 62.69M 63.09M -0.6%
Total puts 21.5K 54.6K -60.6%
Total calls 0 37.6K -100.0%
Total put/call ratio Infinity 1.5 +Infinity%
Largest owners
Shares Value Change
Primecap Management 6.48M $22.54M -0.2%
Russell Investments 5.86M $20.38M +46.1%
NEU Neuberger Berman 5.67M $19.72M +4.9%
BLK BlackRock 5.29M $18.41M +7.2%
Vanguard 4.41M $15.35M +0.1%
Levin Easterly Partners 4.38M $15.26M -12.6%
Indaba Capital Management 3.32M $11.56M +22.1%
Partner Fund Management 3.23M $11.26M +4.0%
Renaissance Technologies 2.79M $9.7M +1.6%
Acadian Asset Management 1.69M $5.87M +32.9%
Largest transactions
Shares Bought/sold Change
RTW Investments 0 -2.11M EXIT
Russell Investments 5.86M +1.85M +46.1%
Driehaus Capital Management 0 -1.67M EXIT
Alyeska Investment 1.12M +1.12M NEW
Schroder Investment Management 0 -803.95K EXIT
Jacobs Levy Equity Management 901.11K +771.91K +597.5%
Endurant Capital Management 1.03M +638.93K +161.5%
Levin Easterly Partners 4.38M -634.56K -12.6%
Indaba Capital Management 3.32M +601.7K +22.1%
Pura Vida Investments 1.09M +590.83K +118.2%

Financial report summary

  • Our financial results and revenue growth rates have varied significantly from quarter-to-quarter and year-to-year due to a number of factors, and a significant variance in our operating results or rates of growth, if any, could lead to substantial volatility in our stock price.
  • We have incurred losses since inception, and we may continue to incur substantial losses for the foreseeable future.
  • The life science markets are highly competitive and subject to rapid technological change, and we may not be able to successfully compete.
  • Market opportunities may not develop as quickly as we expect, limiting our ability to successfully sell our products, or our product development and strategic plans may change and our entry into certain markets may be delayed, if it occurs at all.
  • If our products fail to achieve and sustain sufficient market acceptance, our revenue will be adversely affected.
  • We may experience development or manufacturing problems or delays that could limit the potential growth of our revenue or increase our losses.
  • If our research and product development efforts do not result in commercially viable products within anticipated timelines, if at all, our business and results of operations will be adversely affected.
  • Our products could have defects or errors, which may give rise to claims against us, adversely affect market adoption of our systems, and adversely affect our business, financial condition, and results of operations.
  • Our business depends on research and development spending levels of our customers, a reduction in which could limit our ability to sell our products and adversely affect our business.
  • If one or more of our manufacturing facilities become unavailable or inoperable, we will be unable to continue manufacturing our instruments, IFCs, assays and/or reagents and, as a result, our business will be harmed until we are able to secure a new facility.
  • We generate a substantial portion of our revenue internationally and our international business exposes us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States.
  • We are subject to fluctuations in the exchange rate of the U.S. Dollar and foreign currencies.
  • Any disruption or delay in the shipping or off-loading of our products, whether domestically or internationally, may have an adverse effect on our financial condition and results of operations.
  • We are dependent on single and sole source suppliers for some of the components and materials used in our products, and the loss of any of these suppliers could harm our business.
  • Our future success is dependent upon our ability to expand our customer base and introduce new applications.
  • We may not be able to develop new products or enhance the capabilities of our existing systems to keep pace with rapidly changing technology and customer requirements, which could have a material adverse effect on our business, revenue, financial condition, and operating results.
  • Our business operations depend upon the continuing efforts of our management team and other skilled and experienced personnel, and if we are unable to retain them or to recruit and train new key executives, scientists, and technical support personnel, we may be unable to achieve our goals.
  • Our business growth strategy involves the potential for significant acquisitions, and our operating results and prospects could be harmed if we are unable to integrate future acquisitions successfully.
  • Security breaches, loss of data, cyberattacks, and other information technology failures could disrupt our operations, damage our reputation, and adversely affect our business, operations, and financial results.
  • Our efficiency and cost-savings initiatives could be disruptive to our operations and adversely affect our results of operations and financial condition, and we may not realize some or all of the anticipated benefits of these initiatives in the time frame anticipated or at all.
  • To use our products, our Biomark, EP1, and Helios/CyTOF 2 systems in particular, customers typically need to purchase specialized reagents. Any interruption in the availability of these reagents for use in our products could limit our ability to market our products.
  • If we seek to be regulated as a medical device manufacturer by the U.S. Food and Drug Administration and foreign regulatory authorities, and seek approval and/or clearance for our products, the regulatory approval process would take significant time and expense and could fail to result in FDA clearance or approval for the intended uses we believe are commercially attractive. If our products were successfully approved and/or cleared, we would be subject to ongoing and extensive regulatory requirements, which would increase our costs and divert resources away from other projects. If we obtained FDA clearance or approval and we failed to comply with these requirements, our business and financial condition could be adversely impacted.
  • Our products could become subject to regulation as medical devices by the FDA or other regulatory agencies before we have obtained regulatory clearance or approval to market our products for diagnostic purposes, which would adversely impact our ability to market and sell our products and harm our business.
  • Compliance or the failure to comply with current and future regulations affecting our products and business operations worldwide, such as environmental regulations enacted in the European Union, could cause us significant expense and adversely impact our business.
  • If we fail to maintain effective internal control over financial reporting in the future, the accuracy and timing of our financial reporting may be impaired, which could adversely affect our business and our stock price.
  • Impairment of our goodwill or other intangible assets could materially and adversely affect our business, operating results, and financial condition.
  • Our future capital needs are uncertain and we may need to raise additional funds in the future, which may cause dilution to stockholders or may be upon terms that are not favorable to us.
  • If we fail to comply with the covenants and other obligations under our credit facility, the lenders may be able to accelerate amounts owed under the facilities and may foreclose upon the assets securing our obligations.
  • We are subject to risks related to taxation in multiple jurisdictions and if taxing authorities disagree with our interpretations of existing tax laws or regulations, our effective income tax rate could be adversely affected and we could have additional tax liability.
  • Our ability to use net operating loss carryforwards to offset future taxable income for U.S. federal income tax purposes and other tax benefits may be limited.
  • Adverse conditions in the global economy and disruption of financial markets may significantly harm our revenue, profitability, and results of operations.
  • If we are unable to expand our direct sales and marketing force or distribution capabilities to adequately address our customers’ needs, our business may be adversely affected.
  • If we seek to implement a company-wide enterprise resource planning (ERP) system, such implementation could adversely affect our business and results of operations or the effectiveness of internal control over financial reporting.
  • Changes in accounting principles, or interpretations thereof, could have a significant impact on our financial position and results of operations.
  • We have a significant amount of outstanding indebtedness, and our financial condition and results of operations could be adversely affected if we do not efficiently manage our liabilities.
  • Our ability to protect our intellectual property and proprietary technology through patents and other means is uncertain.
  • We may be involved in lawsuits to protect or enforce our patents and proprietary rights, to determine the scope, coverage and validity of others’ proprietary rights, or to defend against third party claims of intellectual property infringement, any of which could be time-intensive and costly and may adversely impact our business or stock price.
  • We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our employees’ former employers or other institutions or third parties with whom such employees may have been previously affiliated.
  • We depend on certain technologies that are licensed to us. We do not control these technologies and any loss of our rights to them could prevent us from selling our products, which would have an adverse effect on our business.
  • We are subject to certain manufacturing restrictions related to licensed technologies that were developed with the financial assistance of U.S. governmental grants.
  • We are subject to certain obligations and restrictions relating to technologies developed in cooperation with Canadian government agencies.
Management Discussion
  • We generate revenue primarily from sales of our products and services. Our product revenue consists of sales of instruments and consumables. Consumable revenues are largely driven by the size of our installed base of instruments and the annual level of pull-through per instrument. Service revenue is linked to the sales and installed base of our instruments as our service revenue consists of post-warranty service contracts, preventive maintenance plans, instrument parts, installation and training.
  • We sell our instruments to leading academic research institutions, translational research and medicine centers, cancer centers, clinical research laboratories, and biopharmaceutical, biotechnology, and plant and animal research companies. No single customer represented more than 10% of our total revenue for the three and nine months ended September 30, 2019, and 2018. Total revenue from our five largest customers represented 25% and 20% of our total revenue for the three months ended September 30, 2019, and 2018, respectively. Total revenue from our five largest customers represented 20% and 17% of our total revenue for the nine months ended September 30, 2019, and 2018, respectively.
  • The Americas revenue includes revenue generated in the United States of $10.5 million and $13.2 million for the three months ended September 30, 2019, and 2018, respectively. The Americas revenue includes revenues generated in the United States of $32.9 million and $35.4 million for the nine months ended September 30, 2019 and 2018, respectively.
Content analysis ?
H.S. sophomore Good
New words: absence, adjacent, Markham, milestone, paragraph, perfunctory, smaller
Removed: comprised, continuance, iii